Articles of the Month
Videos
Allergy Ranks Highest Impact Factor in Allergy
We are thrilled to announce that the 2024 journal Impact Factors stablished by Clarivate has been released, and we are immensely proud to share that Allergy has been recognised with a Impact Factor of 12.6 as the number one journal in our speciality of Allergy and Clinical Immunology. This outstanding achievement is a testament to the entire team's unwavering commitment and hard work.
The success of Allergy is rooted in several key factors:
Full Commitment and Hard Work: The dedication of our editorial and support teams has been instrumental in driving the journal to new heights.
Rapid Decisions for Submissions: Our efficient submission process ensures that authors receive timely and comprehensive feedback.
Extensive and High-Quality Reviews: We maintain rigorous peer review standards to ensure the publication of only the highest quality research.
Timely Publications: Speedy yet thorough processing of manuscripts guarantees that important research reaches the community promptly.
High Numbers of Impressions and Downloads: The significant engagement with our published papers highlights the journal’s influence and reach within the scientific community.
On behalf of the EAACI Executive Committee, it is our pleasure to extend our heartfelt gratitude to the entire Allergy team.
Special thanks to our Editor-in-Chief, Cezmi Akdis, for his visionary leadership, and our Deputy Editors, Ioana Agache and Marek Jutel, for their invaluable contributions. We also recognize the vital roles of our Associate Editors, including Heimo Breiteneder, Thomas Eiwegger, Wytske Fokkens, Emma Guttman-Yassky, David Jackson, Kari Nadeau, Robyn O’Hehir, Liam O’Mahony, Oliver Pfaar, Alexandra Santos, Claudia Traidl-Hoffmann, De Yun Wang, and Luo Zhang, along with the entire editorial board for their expertise and dedication.
In addition, our heartfelt thanks go to our Managing Editor, Laura Alberch; Graphics Editor, Anna Globinska; Social Media Editor, Ruya Kilic Ogulur; Associate Managing Editor, Marisa McGarry; Production Editor, Sathish Asokan Kannan, and Journal’s Publishing Manager, Lisbeth Cranfield.
Together, we have set a new standard of excellence in Allergy and Clinical Immunology, and we look forward to continuing this upward trajectory. Thank you to everyone who has contributed to making #Allergy a leader in our field!
Maria Torres
EAACI President
Articles
BLOC1S1 Control of Vacuolar Organelle Fidelity Modulates Murine TH2 Cell Immunity and Allergy Susceptibility
Sharma, R., Wu, K., Han, K., et al. Allergy. First published: 31 December 2024
What Is the Next Step for Patients With Aspirin-Exacerbated Respiratory Disease: Biologics With or Without Aspirin Therapy?
Szatkowski, P. and Mastalerz, L. Allergy. First published: 31 December 2024
Soybean Oil in Propofol Is Not Able to Induce Allergic Reactions
Karabacak, D.E., Arzt-Gradwohl, L., Binder, B., et al. Allergy. First published: December 2024
Exhaled Nitric Oxide and Sputum Eosinophils Are Complementary Tools for Diagnosing Occupational Asthma
Doyen, V., Migueres, N., van Kampen, V., et al. Allergy. First published: 27 December 2024
Genotype-Guided Asthma Treatment Reduces Exacerbations in Children: Meta-Analysis of Two RCTs
Slob, E.M.A., Vijverberg, S.J.H., Ruffles, T., et al. Allergy. First published: 26 December 2024
Maternal Allergic Disease Phenotype and Infant Birth Season Influence the Human Milk Microbiome
Ma, J., Palmer, D.J., Geddes, D., et al. Allergy. First published: 26 December 2024
Allergen Specific IgE is a Stronger Predictor of Remission Following Peanut Oral Immunotherapy Than Age in Children Aged 1–10 Years
Ashley, S.E., Lloyd, M., Loke, P., et al. Allergy. First published: 26 December 2024
The Relationship Between Dietary Patterns and the Epidemiology of Food Allergy
Leung, A.S.-Y., Xing, Y., Fernández-Rivas, M. and Wong, G.W.-K. Allergy. First published: 26 December 2024
Exposure Profiles for the Long-Term Use of Disinfectants and Cleaning Products and Asthma
Pacheco Da Silva, E., Weinmann, T., Gerlich, J., et al. Allergy. First published: 26 December 2024
Identification of Gut Biomarkers of FPIES in a Longitudinal Comparative Pediatric Study
Lemoine, A., Kapel, N., Nicolis, I., et al. Allergy. First published: 26 December 2024
Assessing Risk Factors for Relapse Following Omalizumab Discontinuation in Chronic Urticaria
Cihanbeylerden, M., Teixeira, J., Kayıkçı, H., et al. Allergy. First published: 26 December 2024
Allergen-Specific B Cell Responses Following Desensitisation and Natural Tolerance to Cow's Milk Allergy
Shamji, M.H., Kim, E.H., Vazquez-Ortiz, M., et al. Allergy. First published: 22 December 2024
A Differentiated Epithelial Layer Graft Improves Fibrosis and Survival in Airway Stenosis via IL-37
Khalmuratova, R., Kim, Y.S., Kim, D.W. and Shin, H.-W. Allergy. First published: 22 December 2024
Salivary Metabolomic Signatures in Pediatric Eosinophilic Esophagitis
Hiremath, G., Codreanu, S.G., Sherrod, S.D., et al. Allergy. First published: 21 December 2024
Oncostatin-M Is Produced by Human Eosinophils and Expression Is Increased in Uncontrolled Severe Asthma
Esnault, S., Bernau, K., Floerke, H.L., et al. Allergy. First published: 21 December 2024
Global Burden of Asthma and Atopic Dermatitis in 2021: A Systemic Analysis of the Global Burden of Disease Study 2021
Luo, H. and Wen, F. Allergy. First published: 20 December 2024
Food Allergy Genetics and Epigenetics: A Review of Genome-Wide Association Studies
Arnau-Soler, A., Tremblay, B.L., Sun, Y., et al. Allergy. First published: 19 December 2024
Circulating Nitrite in Severe Asthma: Just Another Biomarker or Novel Treatment Target?
Freeman, A., Minnion, M., Lee, P.H., et al. Allergy. First published: 19 December 2024
How FEV1 Improvement Induced by Anti-IL-5 in Severe Type-2 Asthma Is Linked to Mucus Plugs Clearance
Michils, A., Hackx, M., Mlynarski, L., et al. Allergy. First published: 19 December 2024
Multiomic Integration Analysis for Monitoring Severe Asthma Treated With Mepolizumab or Omalizumab
Contreras, N., Escolar-Peña, A., Delgado-Dolset, M.I., et al. Allergy. First published: 18 December 2024
IL-1R2 Expression in Tfr Cells Controls Allergic Anaphylaxis by Regulating IgG Versus IgE Responses
Engeroff, P., Belbezier, A., Vaineau, R., et al. Allergy. First published: 18 December 2024
Deciphering Dysfunctional Regulatory T Cells in Atopic Dermatitis
Kang, S.-J., Gong, J.-R., Jin, S.-P., et al. Allergy. First published: 18 December 2024
Algorithms in Allergy: Assessment of Rhinitis Using Allergen Exposure Chambers
Jutel, M., Zemelka-Wiacek, M., Okamoto, Y. and Pfaar, O. Allergy. First published: 17 December 2024
Exploring Occupational Asthmagen-Related Asthma Phenotypes: A Cluster Analysis and Machine Learning Study
Liao, T.-C., Tsai, P.-C., Lin, M.-C., et al. Allergy. First published: 16 December 2024
The Bronchodilator and Anti-Inflammatory Effect of Long-Acting Muscarinic Antagonists in Asthma: An EAACI Position Paper
Agache, I., Adcock, I.M., Akdis, C.A., et al. Allergy. First published: 16 December 2024
Efficacy and Safety of Dupilumab in Children With Peanut Allergy: A Multicenter, Open-Label, Phase II Study
Sindher, S.B., Nadeau, K.C., Chinthrajah, R.S., et al. Allergy. First published: 14 December 2024
Genome-Wide Association Study Reveals a Causal Relationship Between Allergic Rhinitis and Hazelnut Allergy
Sun, Y., Vonk, J.M., Kersten, E.T.G., et al. Allergy. First published: 14 December 2024
Tralokinumab Treatment in Adult Atopic Dermatitis Patients: 28-Week Evaluation of Clinical Effectiveness, Safety, Serum Proteins and Total IgE Levels
Dekkers, C., Zuithoff, N., Bakker, D., et al. Allergy. First published: 14 December 2024
Dupilumab as an Adjunct to Oral Immunotherapy in Pediatric Patients With Peanut Allergy
Chinthrajah, R.S., Sindher, S.B., Nadeau, K.C., et al. Allergy. First published: 14 December 2024
T Cells Induce Prolonged Downregulation of Barrier Molecules in a Mouse Model of Allergic Contact Dermatitis
Vaher, H., Gadsbøll, A.-S.Ø., Seibel, A.T., et al. Allergy. First published: 14 December 2024
Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe Asthma
Soendergaard, M.B., Hansen, S., Håkansson, K.E.J., et al. Allergy. First published: 14 December 2024
Comparison of Double-Blind and Open Food Challenges for the Diagnosis of Food Allergy in Childhood: The ALDORADO Study
de Weger, W.W., Sprikkelman, A.B., Herpertz, C.E.M., et al. Allergy. First published: 14 December 2024
Causal Associations Between Chronic Spontaneous Urticaria and Thyroid Function Indicators on Different Ethnic Groups: A Bidirectional Two-Sample Mendelian Randomization Analysis
Deng, L., Yao, Y., Lu, Z., et al. Allergy. First published: 13 December 2024
The Presence and Pathogenic Roles of M(IL-33 + IL-2) Macrophages in Allergic Airway Inflammation
Guo, H., Zhao, Y., Zhang, Z., et al. Allergy. First published: 13 December 2024
Kaempferol Exerts Anti-Inflammatory Effects by Accelerating Treg Development via Aryl Hydrocarbon Receptor-Mediated and PU.1/IRF4-Dependent Transactivation of the Aldh1a2/Raldh2 Gene in Dendritic Cells
Takahashi, M., Nagata, K., Watanuki, Y., et al. Allergy. First published: 11 December 2024
Food-Induced Anaphylaxis Reactions at School: A Room for Improvement
Pouessel, G., Divaret-Chauveau, A., Beaumont, P., et al.Allergy. First published: 11 December 2024
An Algorithm for the Diagnosis and Treatment of Food Protein-Induced Enterocolitis Syndrome (FPIES), 2024 Update
Allergy. First published: 10 December 2024
Tetraspanin CD53 Promotes Inflammation but Restrains Mucus Production in a Mouse Model of Allergic Airway Inflammation
Hsu, A.T., Bugajev, V., Gottschalk, T.A., et al. Allergy. First published: 09 December 2024
Indoor Mycotoxin Exposure on Atopic Dermatitis in Companion Dogs
Oh, S., Han, J. and Kim, H.-J. Allergy. First published: 07 December 2024
Real-World Finetuning of Biomarkers in Severe Asthma: Longitudinal Latent Class Analysis From the Italian Registry on Severe Asthma (IRSA)
Bilò, M.B., Martini, M., Antonicelli, L., et al. Allergy. First published: 06 December 2024
Algorithm for the Management of Primary Diffuse Chronic Rhinosinusitis
Fokkens, W.J., de Corso, E., Hellings, P.W., et al. Allergy. First published: 06 December 2024
Endotyping in Chronic Rhinosinusitis—An EAACI Task Force Report
Toppila-Salmi, S., Reitsma, S., Hox, V., et al. Allergy. First published: 06 December 2024
High IgG Anti-IgE Autoantibodies Prevent Early Omalizumab Response in Chronic Spontaneous Urticaria
Niwa, Y., Hayama, K., Toyoshima, S., et al. Allergy. First published: 06 December 2024
Allergen-Specific Immunotherapy and Trained Immunity
Martín-Cruz, L. and Palomares, O. Allergy. First published: 06 December 2024
Citations: 342
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, Aquilina, S, Asero, R, Baker, D, et al. Allergy. 2022; 77: 734– 766
Citations: 147
EAACI guidelines: Anaphylaxis (2021 update)
Muraro A, Worm M, Alviani C, et al. Allergy. 2022; 77: 357–377
Citations: 118
The international WAO/EAACI guideline for the management of hereditary angioedema—The 2021 revision and update
Maurer M, Magerl M, Betschel S, et al. Allergy. 2022; 77: 1961–1990
Citations: 118
The role of peripheral blood eosinophil counts in COVID-19 patients
Xie, G, Ding, F, Han, L, Yin, D, Lu, H, Zhang, M. Allergy. 2021; 76: 471– 482
Citations: 114
Epithelial barrier hypothesis: Effect of the external exposome on the microbiome and epithelial barriers in allergic disease
Celebi Sozener Z, Ozdel Ozturk B, Cerci P, et al. Allergy. 2022; 77: 1418–1449
Citations: 105
Basophil activation test: Mechanisms and considerations for use in clinical trials and clinical practice
Santos, A.F., Alpan, O. and Hoffmann, H.-J. Allergy. 2021; 76: 2420-2432
Citations: 92
Allergenic components of the mRNA-1273 vaccine for COVID-19: Possible involvement of polyethylene glycol and IgG-mediated complement activation
Klimek, L., Novak, N., Cabanillas, B., et al. Allergy. 2021; 76: 3307-3313
Citations: 90
EAACI statement on the diagnosis, management and prevention of severe allergic reactions to COVID-19 vaccines
Sokolowska, M., Eiwegger, T., Ollert, M., Torres, M.J., Barber, D., Del Giacco, S., et al. Allergy. 2021; 76: 1629-1639
Citations: 88/h5>
The role of allergen-specific IgE, IgG and IgA in allergic disease
Shamji MH, Valenta R, Jardetzky T, et al. Allergy. 2021; 76: 3627–3641
Citations: 82
COVID-19 pandemic: Practical considerations on the organization of an allergy clinic—An EAACI/ARIA Position Paper
Pfaar, O, Klimek, L, Jutel, M, Akdis, C, A, Bousquet, J, Breiteneder, H, et al. Allergy. 2021; 76: 648– 676
Citations: 81
Advances and highlights in allergic rhinitis
Zhang Y, Lan F, Zhang L. Allergy. 2021; 76: 3383–3389
Citations: 79
Allergic reactions to the first COVID-19 vaccine: A potential role of polyethylene glycol?
Cabanillas, B., Akdis, C.A. and Novak, N. Allergy. 2021; 76: 1617-1618
Citations: 76
Efficacy and safety of treatment with biologicals for severe chronic rhinosinusitis with nasal polyps: A systematic review for the EAACI guidelines
Agache, I., Song, Y., Alonso-Coello, P., Vogel, Y., Rocha, C., Solà, I., et al. Allergy. 2021; 76: 2337-2353
Citations: 74
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Citations: 73
Endotypes of chronic rhinosinusitis: Relationships to disease phenotypes, pathogenesis, clinical findings, and treatment approaches
Kato A, Peters AT, Stevens WW, Schleimer RP, Tan BK, Kern RC. Allergy. 2022; 77: 812–826
Citations: 70
Vaccines and allergic reactions: The past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., et al. Allergy. 2021; 76: 1640-1660
Citations: 69
Advances and highlights in biomarkers of allergic diseases
Ogulur I, Pat Y, Ardicli O, et al. Allergy. 2021; 76: 3659–3686
Citations: 69
Regulatory B cells, A to Z
Jansen, K., Cevhertas, L., Ma, S., Satitsuksanoa, P., Akdis, M. and van de Veen, W.
Citations: 62
Advances and highlights in asthma in 2021
Agache I, Eguiluz-Gracia I, Cojanu C, et al. Allergy. 2021; 76: 3390–3407
Citations: 62
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Citations: 61
The ingenious mast cell: Contemporary insights into mast cell behavior and function
Dahlin, J.S., Maurer, M., Metcalfe, D.D., Pejler, G., Sagi-Eisenberg, R. and Nilsson, G. Allergy. 2022; 2022; 77: 83-99
The international EAACI/GA²LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria
Zuberbier, T, Abdul Latiff, AH, Abuzakouk, M, et al. Allergy. 2022; 77: 734– 766
The EAACI/GA2LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria
Zuberbier, T., Aberer, W., Asero, R., Abdul Latiff, A., H., Baker, D., Ballmer-Weber, B. et al. Allergy. 2018; 73: 1393- 1414
Risk factors for severe and critically ill COVID-19 patients: A review
Gao, Y-D, Ding, M, Dong, X, et al. Allergy. 2021; 76: 428– 455
Vaccines and allergic reactions: the past, the current COVID-19 pandemic, and future perspectives
Sampath, V., Rabinowitz, G., Shah, M., Jain, S., Diamant, Z., Jesenak, M. et al. Allergy. 2021; 76: 1640-1660
Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19
Azkur, A.,K., Akdis, M., Azkur, D., Sokolowska, M., van de Veen, W., Brüggen, M.,C. et al. Allergy. 2020; 75: 1564– 1581
EAACI guidelines: Anaphylaxis (2021 update)
Muraro, A, Worm, M, Alviani, C, et al. Allergy. 2022; 77: 357– 377
Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen)
Bousquet, J., Khaltaev, N., Cruz, A.A., Denburg, J., Fokkens, W.J., Togias, A. et al. Allergy. 2008; 63: 8-160
Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China
Zhang, J.-J., Dong, X., Cao, Y.-Y., Yuan, Y.-D., Yan, Y.-Q., Akdis, C., A. and Gao, Y.-D. Allergy. 2020; 75: 1730– 1741
Advances and recent developments in asthma in 2020
Cevhertas, L, Ogulur, I, Maurer, DJ, et al. Allergy. 2020; 75: 3124– 3146
The international WAO/EAACI guideline for the management of hereditary angioedema – the 2021 revision and update
Maurer, M., Magerl, M., Betschel, S., et al. Allergy. First published: 10 January 2022
A compendium answering 150 questions on COVID-19 and SARS-CoV-2
Riggioni, C., Comberiati, P., Giovannini, M., Agache, I., Akdis, M., Alves-Correia, M. et al. Allergy. 2020; 75: 2503– 2541
Special Issue: Perspectives in Allergen Immunotherapy: 2019 and Beyond
Volume 74 | Issue S108
Management of anaphylaxis due to COVID-19 vaccines in the elderly
Bousquet, J., Agache, I., Blain, H., et al. Allergy. 2021; 76: 2952-2964
Predictors of treatment response in chronic spontaneous urticaria
Fok, J.S., Kolkhir, P., Church, M.K. and Maurer, M. Allergy. 2021; 76: 2965-2981
Interleukin-31: The “itchy” cytokine in inflammation and therapy
Datsi, A., Steinhoff, M., Ahmad, F., Alam, M. and Buddenkotte, J. Allergy. 2021; 76: 2982-2997
Markers for the involvement of endothelial cells and the coagulation system in chronic urticaria: A systematic review
Mostmans, Y., De Smedt, K., Richert, B., et al. Allergy. 2021; 76: 2998-3016
Eczema herpeticum in atopic dermatitis
Traidl, S., Roesner, L., Zeitvogel, J. and Werfel, T. Allergy. 2021; 76: 3017-3027
CytoBas: Precision component-resolved diagnostics for allergy using flow cytometric staining of basophils with recombinant allergen tetramers
McKenzie, C.I., Varese, N., Aui, P.M., et al. Allergy. 2021; 76: 3028-3040
Heterogeneity of pollen food allergy syndrome in seven Southern European countries: The @IT.2020 multicenter study
Lipp, T, Acar Şahin, A, Aggelidis, X, et al. Allergy. 2021; 76: 3041– 3052
Direct assessment of individual skin barrier components by electrical impedance spectroscopy
Mannweiler, R., Bergmann, S., Vidal-y-Sy, S., Brandner, J.M. and Günzel, D. Allergy. 2021; 76: 3094-3106
Prenatal paraben exposure and atopic dermatitis-related outcomes among children
Thürmann, L, Herberth, G, Seiwert, B, et al. Allergy. 2021; 76: 3122– 3132
Free human DNA attenuates the activity of antimicrobial peptides in atopic dermatitis
Kopfnagel, V, Dreyer, S, Zeitvogel, J, et al. Allergy. 2021; 76: 3145– 3154
Nanoarchitectures for efficient IgE cross-linking on effector cells to study amoxicillin allergy
Tesfaye, A., Rodríguez-Nogales, A., Benedé, S., et al. Allergy. 2021; 76: 3183-3193
Sweet syndrome induced by SARS-CoV-2 Pfizer-BioNTech mRNA vaccine
Darrigade, A.-S., Théophile, H., Sanchez-Pena, P., et al. Allergy. 2021; 76: 3194-3196
Transgenic mice overexpressing the PGE2 receptor EP2 on mast cells exhibit a protective phenotype in a model of allergic asthma
Urbano, A., Plaza, J., Turon, S., et al. Allergy. 2021; 76: 3196-3199
Type 2 biomarker expression (FeNO and blood eosinophils) is higher in severe adult-onset than in severe early-onset asthma
Lommatzsch, M., Klein, M., Stoll, P. and Virchow, J.C. Allergy. 2021; 76: 3199-3202
Identification of Ulocladium chartarum as an important indoor allergen source
Pfeiffer, S., Sandler, P., Raith, M., et al. Allergy. 2021; 76: 3202-3206
Effects of allergen immunotherapy in the MASK-air study: a proof-of-concept analysis
Pfaar, O., Sousa-Pinto, B., Devillier, P., et al. Allergy. 2021; 76: 3212-3214
Predicted number of peanut-allergic patients needed to treat with epicutaneous immunotherapy (EPIT) to prevent one allergic reaction: A novel approach to assessing relevance
Remington, B.C., Koppelman, S.J., Green, T.D., et al. Allergy. 2021; 76: 3223-3226
Legends of allergy and immunology: Sergio Bonini
Maltese, G. and Rasi, G. Allergy. 2021; 76: 3227-3229
Medical algorithm: Peri-operative management of mastocytosis patients
Bocca-Tjeertes, I.F.A., van de Ven, A.A.J.M., Koppelman, G.H., et al. Allergy. 2021; 76: 3233-3235
Open Access Agreements with Wiley
Check here if your research institution has an agreement with Wiley to make your Original Articles and Review Articles free to read, download and share by everyone: Institutional Payments | Wiley
Junior Members Corner
Dear Juniors,
We are thrilled to see the incredible presence of junior members (JMs) at both EAACI and non-EAACI events! The JM assembly (JMA) is working hard to represent all of you, and we are excited to share our recent activities.
In September, several JM representatives attended the ISMA-RHINA 2024 meeting in Helsinki. There, more than 170 participants from over 25 countries met to explore the latest advances in molecular allergology and rhinallergy. The involvement of JMs was significant, with many presenting their research through oral presentations and posters. A highlight of the event was the RHINA Junior session. This session provided practical advice for junior researchers, including strategies for publishing in high-impact journals and the importance of creating clear figures for publications.
Additionally, we participated in the European Respiratory Society (ERS) congress held in Vienna, where we were invited by our Early-Career Members colleagues. This meeting attracted over 20,000 delegates interested in respiratory diseases. Notably, two sessions organized by Early Career members stood out. The first session featured several talks on key aspects of developing a career in respiratory medicine. The second session showcased the traditional “Science Slam”, where five early career members presented their research in an engaging and entertaining manner, making it accessible to a broader audience. During the meeting, we discussed ongoing activities between our two institutions, and we visited the EAACI booth, where we engaged with participants and promoted our initiatives.
Thank you for your continued support, and we look forward to seeing you at future events!
Best regards,
The Junior Member Assembly
EAACI Patients Organisation Committee Corner
The POC Reunion in the Annual Congress 2023
The POC has been participating in the EAACI Annual Congresses and focused meetings such as FAAM and PAAM since 2011. When Covid-19 pandemic and strict public health measures started in 2020, POC members continued attending the EAACI events virtually. For the first time in a long while, the POC returned to in-person participation in the Annual Congress Hamburg 2023.
Fifteen members of the committee attended the Annual Congress 2023 in-person. The special session ESS1 which was completely organised by the POC took place on the first day of the Congress with great success. Session was designed to discuss the “Benefits of engaging with patients in clinical trials and decision-making” with different stakeholders.
Giulia Gabrielli from European Medicine Agency (EMA) shared the framework for engagement between the Agency and the patients. Dr Kirsten Perrett, Director of Australia National Allergy Centre of Excellence, shared their experience in receiving the federal funding for allergy prevention and management in collaboration with the POC member Allergy & Anaphylaxis Australia. Susanna Palkonen, Director of European Federation of Allergy and Airways Diseases Patients Associations (EFA) presented their long-lasting track record in participation to research projects. POC Member Mikaela Odemyr, President of Asthma and Allergy Association Sweden shared her experience as a patient representative in participating the research design and planning process.
The session chairs were Carla Jones, CEO of Allergy UK, past POC Co-Chair and Ozlem Ceylan, President of Living with Allergy Association, current POC Chair. The session also had a panel discussion where chairs invited the audience to share their experiences and best practises.
Additionally, POC members Sabine Schnadt (DAAB-Germany) presented “Managing the risk of patients with peanut allergy: the value of thresholds of reaction” in the industry session, Patricia Carmelo and Carolina Olivares (Fundacion Creciendo con Alergias Alimenarias-Chile) had two poster presentations; “Food Allergens that trigger anaphylaxis in children in Chile” and “Adrenaline Auto-injector in Chile, National Survey 2020”.
Several POC members attended the Beat Allergy Run & Walk on the 10th of June. The event was organised to contribute on providing much-needed aid as the collected funds were sent to those affected by the earthquakes in Turkey.
The POC believes the conferences and in-person meetings are useful in staying up to date with new developments in medicine, dissemination of knowledge, enabling interaction with opinion leaders, networking, developing consensus, and adoption of newer ideas relevant to the patient community. Going forward, committee members consider hybrid conventions a decent opportunity to increase accessibility and inclusivity. In 2024, POC is planning to attend the Annual Congress in Valencia and FAAM in Athens.
